Healthcare provider profile · identity verified

Raymond E Banfer, MD

Allopathic & Osteopathic Physicians|Family Medicine · CUMBERLAND, MD · NPI 1093714057

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Raymond E Banfer, MD received $15.22 in general payments during 2025 across 1 reported records.

Tactile Systems Technology Inc accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$15.22

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Tactile Systems Technology Inc Unresolved — no canonical attribution shown $15.22100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$15.221

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Flexitouch Plus
Normalized: flexitouch plus
Device Tactile Systems Technology Inc $15.22 1 2025
Source payment records
Nimbl
Normalized: nimbl
Device Tactile Systems Technology Inc $15.22 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Levothyroxine SodiumLevothyroxine Sodium20564
LisinoprilLisinopril19758
Atorvastatin CalciumAtorvastatin Calcium14850
Amlodipine BesylateAmlodipine Besylate14446
OmeprazoleOmeprazole13952
HydrochlorothiazideHydrochlorothiazide11036
Pravastatin SodiumPravastatin Sodium10830
Albuterol Sulfate HfaAlbuterol Sulfate10636
Losartan PotassiumLosartan Potassium9134
Metformin HclMetformin Hcl9028
GabapentinGabapentin8519
Metoprolol TartrateMetoprolol Tartrate8526
Zolpidem TartrateZolpidem Tartrate85suppressed
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72suppressed
FamotidineFamotidine7125
FurosemideFurosemide7130
Potassium ChloridePotassium Chloride7022
Pantoprazole SodiumPantoprazole Sodium6628
Tramadol HclTramadol Hcl6519
SimvastatinSimvastatin6015
Metoprolol SuccinateMetoprolol Succinate5921
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide5815
Fluticasone PropionateFluticasone Propionate5323
Tamsulosin HclTamsulosin Hcl5016
PregabalinPregabalin49suppressed
Escitalopram OxalateEscitalopram Oxalate4717
AlprazolamAlprazolam4612
PrednisonePrednisone4433
Sertraline HclSertraline Hcl4416
Ventolin HfaAlbuterol Sulfate4317
LorazepamLorazepam37suppressed
MeloxicamMeloxicam3711
DiazepamDiazepam36suppressed
AtenololAtenolol30suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl3011
Rosuvastatin CalciumRosuvastatin Calcium3013
EliquisApixaban2911
Esomeprazole MagnesiumEsomeprazole Magnesium26suppressed
SpironolactoneSpironolactone2611
Fluoxetine HclFluoxetine Hcl25suppressed
GlipizideGlipizide25suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25suppressed
Tizanidine HclTizanidine Hcl25suppressed
Montelukast SodiumMontelukast Sodium24suppressed
Ondansetron HclOndansetron Hcl24suppressed
Trazodone HclTrazodone Hcl24suppressed
Alendronate SodiumAlendronate Sodium22suppressed
GlimepirideGlimepiride22suppressed
IbuprofenIbuprofen22suppressed
Advair HfaFluticasone Propion/Salmeterol21suppressed
AllopurinolAllopurinol21suppressed
CarvedilolCarvedilol21suppressed
Enalapril MaleateEnalapril Maleate21suppressed
Hydroxyzine HclHydroxyzine Hcl21suppressed
MounjaroTirzepatide21suppressed
ClonazepamClonazepam20suppressed
Ondansetron OdtOndansetron20suppressed
XareltoRivaroxaban20suppressed
JardianceEmpagliflozin19suppressed
BaclofenBaclofen18suppressed
CelecoxibCelecoxib17suppressed
LovastatinLovastatin17suppressed
OzempicSemaglutide17suppressed
Ropinirole HclRopinirole Hcl17suppressed
TradjentaLinagliptin17suppressed
Ultra-Fine Short Pen NeedlePen Needle, Diabetic17suppressed
Citalopram HbrCitalopram Hydrobromide16suppressed
TopiramateTopiramate16suppressed
ClopidogrelClopidogrel Bisulfate15suppressed
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15suppressed
Doxycycline HyclateDoxycycline Hyclate14suppressed
Oxycodone HclOxycodone Hcl14suppressed
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13suppressed
FarxigaDapagliflozin Propanediol13suppressed
JanuviaSitagliptin Phosphate13suppressed
LoperamideLoperamide Hcl13suppressed
Olmesartan MedoxomilOlmesartan Medoxomil13suppressed
Oxybutynin Chloride ErOxybutynin Chloride13suppressed
Atomoxetine HclAtomoxetine Hcl12suppressed
AzithromycinAzithromycin12suppressed
CalcitriolCalcitriol12suppressed
Clonidine HclClonidine Hcl12suppressed
LactuloseLactulose12suppressed
Humalog Kwikpen U-100Insulin Lispro11suppressed
SynthroidLevothyroxine Sodium11suppressed
Triamcinolone AcetonideTriamcinolone Acetonide11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $15.22 · 1 records Tactile Systems Technology Inc Flexitouch Plus, Nimbl
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error